Treatment of rheumatoid arthritis and the liver

1. Younossi ZM. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008 Jul; 28(1): 2-12.

2. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 Jun; 41(6): 1313-21.

3. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002 Aug; 36(2): 479-97.

4. Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol 2009 Jun; 3(3): 269-91.

5. Invernizzi P, Selmi C, Gershwin ME. Update on primary biliary cirrhosis. Dig Liver Dis Jun; 42(6): 401-8.

6. Hudson M, Rojas-Villarraga A, Coral-Alvarado P, Lopez-Guzman S, Mantilla RD, Chalem P, et al. Polyautoimmunity and familial autoimmunity in systemic sclerosis. J Autoimmun 2008 Sep; 31(2): 156-9.

7. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009 Aug; 51(2): 237-67.

8. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000 Dec; 32(6): 1196-9.

9. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007 Mar; 136(5): 699-712.

10. Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 2009 Nov; 36(11): 2416-20.

11. European Association For The Study Of The L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009 Feb; 50(2): 227-42.

12. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009 Sep; 50(3): 661-2.

13. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009 Apr; 49(4): 1335-74.

14. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003 Nov; 62(11): 1078-82.

15. Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis 2006 May; 10(2): 207-17, vii.

16. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006 Mar; 43(3): 618-31.

17. Paulus HE. FDA Arthritis Advisory Committee meeting. Arthritis Rheum 1982 May; 25(5): 595-6.

18. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007 Jan; 132(1): 272-81.

19. Šedová L, Horák P, Pavelka K. Doporučení České revmatologické společnosti pro monitorování bezpečnosti léčby revmatoidní artritidy. Čes Revmatol 2009; 17(1): 4-15.

20. Bridges SL, Jr., Alarcon GS, Koopman WJ. Methotrexate-induced liver abnormalities in rheumatoid arthritis. J Rheumatol 1989 Sep; 16(9): 1180-3.

21. Rau R, Karger T, Herborn G, Frenzel H. Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate. J Rheumatol 1989 Apr; 16(4): 489-93.

22. Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989 Feb; 32(2): 121-7.

23. Kremer JM, Alarcon GS, Lightfoot RW, Jr., Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994 Mar; 37(3): 316-28.

24. Tishler M, Caspi D, Halperin Z, Baratz M, Moshkowitz M, Yaron M. A prospective analysis of liver biopsies in rheumatoid arthritis patients receiving long term methotrexate therapy. Rheumatol Int 1992; 12(1): 39-41.

25. Perry MC. Chemotherapeutic agents and hepatotoxicity. Semin Oncol 1992 Oct; 19(5): 551-65.

26. Suissa S, Ernst P, Hudson M, Bitton A, Kezouh A. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med 2004 Jul 15; 117(2): 87-92.

27. Weinblatt ME, Dixon JA, Falchuk KR. Serious liver disease in a patient receiving methotrexate and leflunomide. Arthritis Rheum 2000 Nov; 43(11): 2609-11.

28. www.arava.com.

29. Farr M, Symmons DP, Bacon PA. Raised serum alkaline phosphatase and aspartate transaminase levels in two rheumatoid patients treated with sulphasalazine. Ann Rheum Dis 1985 Nov; 44(11): 798-800.

30. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis May 6.

31. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008 Oct; 58(10): 2968-80.

32. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008 Mar 22; 371(9617): 987-97.